Phase 2 N=69 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
Kidney Cancer
Primary: Progression Free Survival (PFS) — 2.7; 5.2 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=495 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Advanced Gastrointestinal Cancer
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 115; 41; 87; 156 Participants
Phase 2 N=101 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
Metastatic Pancreatic Cancer · Colorectal Cancer · Esophageal Neoplasms
Primary: Percentage of Participants With Dose Limiting Toxicities (DLTs) in Western Safety Cohort — 50 percentage of participants
Phase 2 N=46 Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene
ADA-SCID
Primary: Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year) — 100; 85.71; 100; 92.31 percentage of participants
Phase 2 N=46 A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Participants and Severity of AEs — 8; 8; 9; 3 Number
Phase 2 N=35 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 25.7 percentage of participants
Phase 2 N=30 Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
Scar Prevention
Primary: Part B: Expert Panel Scar Assessment Score — -3.16; 0.18; 1.45; 2.91 millimeters
Phase 2 N=19 High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Cancer
Primary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale
Phase 2 N=223 A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
Radiation Induced Oral Mucositis
Primary: Duration (in Days) of Radiation Induced Severe Oral Mucositis (OM) Per World Health Organization (WHO) Criteria — 8; 1.5; 19 days
Phase 2 N=304 Dose Range Study of CD5789 in Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Participants With Success Rate 1 (SR1) — 29.51; 32.79; 26.67; 32.79 percentage of participants — p=0.096
Phase 2 N=29 Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
Attention-Deficit Hyperactivity Disorder
Primary: PK Parameters for Rate and Extent of Absorption of MPH: Lag Time — 6.3; 3.3 hours
Phase 2 N=244 Memory Aid by Intranasal Insulin in Diabetes (MemAID)
Type 2 Diabetes Mellitus
Primary: Gait Speed Normal Walk (cm/s). — 112.23; 103.42; 121.58; 119.51 cm/s — p=0.025
Phase 2 N=477 Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
Plasmodium Falciparum Malaria
Primary: PCR-Corrected ACPR at Day 28 — 95; 99; 99 percentage of subjects
Phase 2 N=22 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Fuchs' Corneal Endothelial Dystrophy (FCED)
Primary: Incidence and Severity of Ocular TEAEs. — 3; 6; 1; 1 Participants
Phase 2 N=231 Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Acute Episode of Overt Hepatic Encephalopathy · Hepatic Encephalopathy
Primary: Percentage of Participants in Each HE Stage — 11; 6; 30; 40 percentage of participants